病毒学
病毒
抗病毒药物
核糖核酸
病毒复制
冠状病毒
RNA聚合酶
聚合酶
呼吸道感染
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
呼吸系统
生物
医学
酶
2019年冠状病毒病(COVID-19)
基因
解剖
传染病(医学专业)
疾病
生物化学
病理
作者
Julien Sourimant,Carolin M. Lieber,Megha Aggarwal,Robert M. Cox,Josef D. Wolf,Jeong-Joong Yoon,Märt Toots,Chengjin Ye,Zachary M. Sticher,Alexander A. Kolykhalov,Luis Martínez‐Sobrido,Gregory R. Bluemling,Michael G. Natchus,George R. Painter,Richard K. Plemper
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2022-01-14
卷期号:375 (6577): 161-167
被引量:114
标识
DOI:10.1126/science.abj5508
摘要
Preparing antiviral defenses Antiviral drugs are an important tool in the battle against COVID-19. Both remdesivir and molnupiravir, which target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase, were first developed against other RNA viruses. This highlights the importance of broad-spectrum antivirals that can be rapidly deployed against related emerging pathogens. Sourimant et al . used respiratory syncytial virus (RSV) as a primary indication in identifying further drugs that target the polymerase enzyme of RNA viruses. The authors explored derivatives of molnupiravir and identified 4′ fluorouridine (EIDD-2749) as an inhibitor of the polymerase of RSV and SARS-CoV-2. This drug can be delivered orally and was effective against RSV in mice and SARS-CoV-2 in ferrets. —VV
科研通智能强力驱动
Strongly Powered by AbleSci AI